Trial Profile
A Phase 2 to Evaluate the Dose-Response Relationship and Safety of JTT-751 in Patients with Iron Deficiency Anemia
Status:
Completed
Phase of Trial:
Phase II
Latest Information Update: 31 Jan 2022
Price :
$35
*
At a glance
- Drugs Ferric citrate (Primary)
- Indications Iron deficiency anaemia
- Focus Therapeutic Use
- Sponsors Japan Tobacco
- 01 Sep 2017 Status changed from recruiting to completed.
- 22 Jul 2016 New trial record